Xylazine's Hidden Target: A New Way to Combat Its Effects?

Xylazine, a drug often mixed with opioids, is causing serious health issues in the United States. While it's mainly known for affecting α2-adrenergic receptors, its harmful effects can't be fully reversed by drugs that block these receptors. Scientists have now found that xylazine also targets α7 nicotinic acetylcholine receptors (α7 nAChRs). In experiments, xylazine blocked these receptors' response to acetylcholine in frog egg cells and in PC12 cells. Interestingly, curcuminoids, ivermectin, and a specific drug called PNU120596 can counteract xylazine's inhibition. Since α7 nAChRs play a key role in reducing inflammation and are found throughout the body, this discovery could lead to new ways to treat xylazine-related harm. Using curcuminoids or repurposing ivermectin might provide an immediate and effective solution.